In Oct 2007, the FDA declared the labeling for all PDE5 inhibitors, which include tadalafil, needs a additional outstanding warning with the prospective danger of sudden Listening to loss as the results of post-advertising reports of short term deafness related to usage of PDE5 inhibitors.[19]"This technology goes in which no other cure possibility